Search results for "LENA"

showing 10 items of 259 documents

Teràpia cognitiva basada en la consciència plena, aplicada a pacients oncològics

2016

espanolEn este estudio se pone a prueba la viabilidad de la Terapia Cognitiva basada en la Consciencia Plena para mejorar la calidad de vida y el bienestar de los pacientes de cancer. La muestra esta constituida por siete pacientes de cancer de mama de la Comunidad Valenciana de edades comprendidas entre los 40 y 68 anos. Las pacientes fueron evaluadas psicologicamente antes de participar en un taller en el que se ofrecieron 8 sesiones de Mindfulness siguiendo el protocolo propuesto por Segal et al. (2002).Una vez finalizado el taller, las pacientes fueron evaluadas de nuevo y se contrastaron los cambios acaecidos tras la participacion del programa. Los resultados muestran efectos directos …

Mindfulness càncer teràpia cognitiva consciència plena. ArtículoGeneral Earth and Planetary Sciences:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAGeneral Environmental Science
researchProduct

PETTERDITE, THE Cr-DOMINANT ANALOGUE OF DUNDASITE, A NEW MINERAL SPECIES FROM DUNDAS, TASMANIA, AUSTRALIA AND CALLENBERG, SAXONY, GERMANY

2000

Petterdite is a newly discovered hydrated lead chromium hydroxyl carbonate, the Cr 3+ -dominant analogue of dundasite, with a formula PbCr 2 (CO 3 ) 2 (OH) 4 ·H 2 O. The type locality is the Red Lead mine, on the Zeehan–Dundas mining field in northwestern Tasmania, Australia. The mineral also occurs in small amounts at the Callenberg nickel deposit, Saxony, Germany. Petterdite forms thin crusts made up of tiny platy crystals up to about 15 μm across, associated with crocoite and anglesite at the type locality, and with crocoite, cerussite, bindheimite, pyromorphite, and relict galena at Callenberg. The petterdite crusts are pale greyish to pinkish violet and non-fluorescent; they have an ea…

Mineralchemistry.chemical_elementengineering.materialCrocoiteCrystallographyPyromorphiteChromiumchemistryGeochemistry and PetrologyGalenaAnglesiteengineeringPleochroismMohs scale of mineral hardnessThe Canadian Mineralogist
researchProduct

Distribution of trace elements in willemite from the Belgium non-sulphide deposits

2019

Samples of willemite (Zn2SiO4) mineralization from the historical non-sulphide Zn–Pb deposits of La Calamine (eastern Belgium) have been recovered from collections of the Geological Survey of Belgium. Textural and chemical analyses are used to evaluate the critical element distribution (Ge, In, Ga) and deportment. willemite occurs as a variety of types that continuously formed between the protore stage (sulphides) and the late supergene stage (carbonates and hydrated phases). Different types of willemite may be distinguished on the basis of their shape and zoning characteristics, supporting a polyphase non-sulphide mineralization after the protore stage. This is also marked by a significant…

Mineralization (geology)ChemistryGermanium05 social sciencesWillemiteGeochemistrychemistry.chemical_element[SDU.STU]Sciences of the Universe [physics]/Earth SciencesWillemiteZincengineering.materialHydrothermal circulationSupergeneNon-sulphide zinc depositsSphaleriteGeochemistry and PetrologyGalena[SDU]Sciences of the Universe [physics]0502 economics and businessCritical elementsengineering050211 marketingInductively coupled plasma050203 business & management[SDU.STU.MI]Sciences of the Universe [physics]/Earth Sciences/MineralogyEuropean Journal of Mineralogy
researchProduct

Il complesso monastico di Santa Maria Maddalena di Corleone

2019

Le inedite fonti archivistiche indagate del monastero di Santa Maria Maddalena di Corleone hanno permesso di conoscere le committenze delle nobili e facoltose badesse per l’antico complesso benedettino, che miravano a rinnovare, arricchire e ornare gli spazi sacri rivolgendosi ad artisti di chiara fama. Da Tommaso de Vigilia ad Antonello Gagini, ad Antonio Vasquez e ancora a noti marmorarii, stuccatori, intagliatori e argentieri riservando la realizzazione delle opere a ricamo alle abili consorelle della stessa fondazione monastica. Del prezioso patrimonio ricordato dalle carte d’archivio si rintracciano alcune importanti opere, come i preziosi paliotti ricamati arricchiti ora con perline s…

Monastery of Santa Maria Maddalena decorative arts painting sculpture silverware sacred furnishings Corleone SiciliaSettore L-ART/02 - Storia Dell'Arte ModernaMonastero di Santa Maria Maddalena arti decorative pittura scultura argenti arredi sacri Corleone Sicilia
researchProduct

Zvaigžņotā Debess: 2004/05, Ziema

2004

Contents: Ņ.Ozoliņa. Earthquakes in Latvia ; I.Daube. Space Craft “Ranger-7” ; M. Gailis. Moon Investigation in Riga ; J.Tambergs. Problems of Dialogue between Quantum Mechanics and Theology (concluded) ; Z Alksne, A.Alksnis. Ultra-Cool Dwarf Pair Weighed ; A.Balklavs. Successful Hunt of Protostars ; A.Balklavs. Silhouette of a Black Hole ; A.Balklavs. A Distant Giant Quasar ; A.Balklavs. Cosmic Objects in Captivating Photos – 3 ; J.Freimanis. Extragalactic Planetary Nebulae ; J.Jaunbergs. Cassini Enters the Saturnian System ; D.Krieviņš. Space Launchers of Early XXI Century. The Commonwealth of Independent States (CIS) ; J.Bārzdiņš. Professor Rusins-Martins Freivalds on the Path of Science…

Novembra kāvi Baltijas debesīsGalēji auksto punduru sistēma 2MASSW J0746425+2000321Herbiga-Haro objekti HH-30 HH-34 HH-47Krustvārdu mīklaLīgatnes meteorīts – hipotēzeProtozvaigznesPlanetārie miglāji – NGC 2392 (Eskimosa miglājs) NGC 6369 (Spociņa miglājs)Starptautiskā komandu olimpiāde “Baltijas ceļš – 2003” – uzdevumu atrisinājumiRisina lasītājsNASA Genesis – Saules vēja paraugiLU profesors Rūsiņš-Mārtiņš FreivaldsZemestrīces LatvijāBlumbaha spoguļteleskops BSTPirmās galaktikasCassini misija Saturna sistēmāJakobs Juliuss ZeibotsJupitera pavadoņa Jo putekļiRīgas topogrāfiskā uzmērīšanaSavādnieki eksaktajās zinātnēs – Dž.Maksvels O.Sevisaids H.Hercs V.Pauli V.Heizenbergs B.Mandelbrots A.Vītols J.Vītols G.Šipovs A.AkimovsMeteorītu panspermijaPlanetārie miglāji N52 N66 N192 SMP93 Lielajā Magelāna MākonīVenēras un Merkura aizklāšanāsKosmiskie transportlīdzekļi – NVSAstronomiskās parādības - 2005Melnais caurums – siluetsKalenaisa – “Hebridu Stounhendža”Planētu redzamības kompleksā diagramma 2005Zvaigžņu lietus novembrīESA Smart-1Astronomiskās parādības - 2004Kvantu mehānika un teoloģijaMilzu kvazārs J1432+158Londonas universitātes Berkbeka koledža
researchProduct

Conceptual design and infrastructure for the installation of the first AGATA sub-array at LNL

2011

WOS: 000295765100014

Nuclear and High Energy PhysicsDANTE Heavy-ion DetectorPhysics::Instrumentation and DetectorsHELENA multiplicity filter01 natural sciences7. Clean energyParticle detectorNuclear physicsPRISMA spectrometerConceptual design0103 physical sciences[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]Nuclear Experiment010306 general physicsGamma detectionInstrumentationTRACE SI detectorPhysicsSpectrometer010308 nuclear & particles physicsbusiness.industrySemiconductor detectorCologne plungerAGATAAGATADANTE heavy-ion-detectorbusinessComputer hardwareNuclear Instruments and Methods in Physics Research
researchProduct

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

2021

PETHEMA/GEM Cooperative Group.

OncologyAdultBoron CompoundsMalemedicine.medical_specialtyNeoplasm ResidualPhysics::Instrumentation and DetectorsClinical Trials and ObservationsImmunologyPatient subgroupsGlycineDrug resistanceBiochemistryDexamethasoneBortezomibhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmHumansProgression-free survivalTreatment resistanceLenalidomideComplete responseMultiple myelomaAgedChromosome AberrationsLymphoid Neoplasiabusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseFlow CytometryProgression-Free Survivalbody regionsClinical trialTreatment OutcomeDrug Resistance NeoplasmFemalebusinessMultiple Myeloma
researchProduct

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

2017

International audience; Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combina…

OncologyCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-Cell[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMedicineChemotherapy ; clinical trials ; mantle cell lymphoma ; molecular targeted therapyBortezomibCombination chemotherapyclinical trialChemotherapy; clinical trials; mantle cell lymphoma; molecular targeted therapy; Hematology; Oncology; Cancer ResearchHematologyTemsirolimusEuropeLocalOncology030220 oncology & carcinogenesisIbrutinibPractice Guidelines as TopicRituximabRituximabmedicine.drugmedicine.medical_specialtymolecular targeted therapymantle cell lymphoma03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineHumansChemotherapyLenalidomideclinical trialsbusiness.industryPhase II as TopicMantle-Cellmedicine.diseaseClinical trialChemotherapy; clinical trials; mantle cell lymphoma; molecular targeted therapy; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase II as Topic; Drug Resistance Neoplasm; Europe; Humans; Lymphoma Mantle-Cell; Neoplasm Recurrence Local; Practice Guidelines as Topic; RituximabNeoplasm RecurrencechemistryDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusiness030215 immunology
researchProduct

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.

2021

Over the past 10 years, the treatment of multiple myeloma (MM) dramatically changed due to the introduction of a number of new agents and combination regimens both in the frontline and in the relapsed/refractory setting. Currently, at least 11 classes of therapeutic agents, including steroids, alkylators (melphalan and cyclophosphamide), proteasome inhibitors (PI: bortezomib, carfilzomib, ixazomib), immunomodulatory agents (thalidomide, lenalidomide, pomalidomide), monoclonal antibodies (mAbs: elotuzumab, daratumumab), HDAC-inhibitors (panobinostat), BCL2 inhibitors (venetoclax), selective inhibitors of nuclear export (selinexor), drug-conjugated mAbs (belantamab mafodotin), bispecific agen…

OncologyCancer Researchmedicine.medical_specialtyOpinionlenalidomidelcsh:RC254-282chemistry.chemical_compoundInternal medicinemedicineLenalidomideIsatuximabcarfilzomibBortezomibbusiness.industrynetwork meta analysisbortezomibDaratumumabRefractory Multiple Myelomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdaratumumabCarfilzomibmyelomachemistryOncologyMeta-analysisbusinessmedicine.drugisatuximabFrontiers in oncology
researchProduct

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma P…

2021

Abstract Background: In newly-diagnosed multiple myeloma (NDMM), lenalidomide/bortezomib/dexamethasone (RVd) is one of the most widely used combination regimens. Anti-CD38 monoclonal antibodies (CD38-moAb) increase efficacy when added to standard-of-care regimens. Here we present the first primary endpoint of the randomized, open-label, multicenter, phase III GMMG-HD7 trial, comparing RVd without (arm IA) or with the CD38-moAb isatuximab (Isa, arm IB) with regard to the rate of minimal residual disease (MRD) negativity after induction therapy in patients with transplant-eligible NDMM. Patients and Methods: Patients with transplant-eligible NDMM at 67 sites in Germany were equally randomized…

OncologyIsatuximabmedicine.medical_specialtybusiness.industryBortezomibImmunologyCell BiologyHematologyNewly diagnosedmedicine.diseaseBiochemistryInternal medicineInduction therapyMedicinebusinessMultiple myelomaDexamethasoneLenalidomidemedicine.drugBlood
researchProduct